Product Main

Quick Details

Purity: >99%
Model Number: 1195765-45-7
Brand Name: NJBN STEROID
Grade Standard: Medicine Grade
Type: Auxiliaries and Other Medicinal Chemicals
Place of Origin: China (Mainland)
EINECS No.: 200-366-3
MF: C23H20F3N5O2S2
Other Names: Dabrafenib;N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]
CAS No.: 1195765-45-7
Model No: CAS: 159351-69-6
Usage: Animal Pharmaceuticals
Standard: Enterprise Standard
Delivery: Express courier

Specifications

GSK2118436 Safe Shipping CAS 1195765-45-7 Dabrafenib for Skin Cancer


Quick Detail:

Product name Dabrafenib
Synonyms Dabrafenib; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; Dabrafenib free base(GSK2118436A); Dabrafenib(GSK2118436); GSK2118436A; Dabrafenib (GSK2118436); Dabrafenib KB-57246; Debrafenib API
CAS NO 1195765-45-7
MF C23H20F3N5O2S2
MW 519.5624096
EINECS 200-366-3
Appearance White to slightly yellowish-white crystalline
Assay 99%min
Storage Shading, confined preservation
Brand NJBN STEROID
Delivery EMS, DHL, TNT, FedEx, UPS
Delivery time within 24 hours upon receipt of payment
Product Category Raf B protein kinase inhibitor; inhibitor; MAPK; Inhibitors

Description:

Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
The Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600Emutation-positive advanced melanoma on May 30, 2013. Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months. To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib. On January 8, 2014, the FDA approved this combination of dabrafenib and trametinib for BRAF V600E/K-mutant metastatic melanoma.

Application:
Dabrafenib is used to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

Hi, I'm teresa, everybody is taking the similar words, what I? Want to say is: Just give me a? Chance, Just have a? Try on me, maybe you will get a? Big surprise on me, come to join us, Buddy!